Cargando…

First‐in‐human study of milvexian, an oral, direct, small molecule factor XIa inhibitor

Milvexian (BMS‐986177/JNJ‐70033093) is a small molecule, active‐site inhibitor of factor XIa (FXIa) being developed to prevent and treat thrombotic events. The safety, tolerability, pharmacokinetics (PKs), and pharmacodynamics (PDs) of milvexian were assessed in a two‐part, double‐blind, placebo‐con...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perera, Vidya, Wang, Zhaoqing, Luettgen, Joseph, Li, Danshi, DeSouza, Mary, Cerra, Michael, Seiffert, Dietmar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841437/ https://www.ncbi.nlm.nih.gov/pubmed/34558200 http://dx.doi.org/10.1111/cts.13148

Ejemplares similares

Effects of rifampin on the pharmacokinetics and pharmacodynamics of milvexian, a potent, selective, oral small molecule factor XIa inhibitor
por: Perera, Vidya, et al.
Publicado: (2022)

Effects of Itraconazole and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Milvexian, A Factor XIa Inhibitor
por: Perera, Vidya, et al.
Publicado: (2022)

Corrigendum: First‐in‐human study of milvexian, an oral, direct, small molecule factor XIa inhibitor
Publicado: (2022)

Safety, pharmacokinetics, and pharmacodynamics of milvexian in healthy Japanese participants
por: Perera, Vidya, et al.
Publicado: (2022)

Milvexian, an orally bioavailable, small‐molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits
por: Wong, Pancras C., et al.
Publicado: (2021)

First‐in‐human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS‐962212, a direct, reversible, small molecule factor XIa inhibitor in non‐Japanese and Japanese healthy subjects
por: Perera, Vidya, et al.
Publicado: (2018)

Single-Dose Pharmacokinetics of Milvexian in Participants with Normal Renal Function and Participants with Moderate or Severe Renal Impairment
por: Perera, Vidya, et al.
Publicado: (2022)

Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants
por: Perera, Vidya, et al.
Publicado: (2022)

Antithrombotic Effects of the Novel Small-Molecule Factor XIa Inhibitor Milvexian in a Rabbit Arteriovenous Shunt Model of Venous Thrombosis
por: Wang, Xinkang, et al.
Publicado: (2023)

Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa
por: Heitmeier, Stefan, et al.
Publicado: (2022)

Metabolism and Disposition of the Novel Oral Factor XIa Inhibitor Asundexian in Rats and in Humans
por: Piel, Isabel, et al.
Publicado: (2023)

First-In-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SHR2285, a Small-Molecule Factor XIa Inhibitor in Healthy Subjects
por: Chen, Rui, et al.
Publicado: (2022)

Discovery of Benzyl Tetraphosphonate Derivative as Inhibitor of Human Factor Xia
por: Kar, Srabani, et al.
Publicado: (2020)

ThromboprophylaXIs with Factor XI/XIa inhibitors for venous thromboembolism
por: Porres-Aguilar, Mateo
Publicado: (2023)

First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa
por: Thomas, Dirk, et al.
Publicado: (2021)

Decision making in xia2
por: Winter, Graeme, et al.
Publicado: (2013)

In Memorium of Dr. Bing Xia
por: Qian, Jiaming, et al.
Publicado: (2015)

Efficacy and Safety of Oral Factor XIa Inhibitors in Stroke Prevention: A Systematic Review and Meta-Analysis
por: Palaiodimou, Lina, et al.
Publicado: (2023)

Lignosulfonic Acid Sodium Is a Noncompetitive Inhibitor of Human Factor XIa
por: Kar, Srabani, et al.
Publicado: (2021)

Venous Thromboembolism Prophylaxis in Major Orthopedic Surgeries and Factor XIa Inhibitors
por: Jones, Aaryana, et al.
Publicado: (2023)

Designing Allosteric Inhibitors of Factor XIa. Lessons from the Interactions of Sulfated Pentagalloylglucopyranosides
por: Al-Horani, Rami A., et al.
Publicado: (2014)

Xia-Gibbs Syndrome: A Review of Literature
por: Goyal, Chanan, et al.
Publicado: (2020)

Design and Preclinical Characterization Program toward Asundexian (BAY 2433334), an Oral Factor XIa Inhibitor for the Prevention and Treatment of Thromboembolic Disorders
por: Roehrig, Susanne, et al.
Publicado: (2023)

Factor XIa Inhibitors as a Novel Anticoagulation Target: Recent Clinical Research Advances
por: Xia, Yunqing, et al.
Publicado: (2023)

AHDC1 missense mutations in Xia-Gibbs syndrome
por: Khayat, Michael M., et al.
Publicado: (2021)

Faktor-XIa-Hemmer: Antikoagulation auf höherem Sicherheitsniveau?
por: Overbeck, Peter, et al.
Publicado: (2022)

Allosteric Inhibition of Human Factor XIa: Discovery of Monosulfated Benzofurans as a Class of Promising Inhibitors
por: Argade, Malaika D., et al.
Publicado: (2014)

Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa
por: Yi, B. Alexander, et al.
Publicado: (2021)

A Systematic Review of the Mysterious Caterpillar Fungus Ophiocordyceps sinensis in Dong-ChongXiaCao (冬蟲夏草 Dōng Chóng Xià Cǎo) and Related Bioactive Ingredients
por: Lo, Hui-Chen, et al.
Publicado: (2013)

Selection and characterization of a DNA aptamer inhibiting coagulation factor XIa
por: Donkor, David A., et al.
Publicado: (2017)

Characterization of the flavoenzyme XiaK as an N-hydroxylase and implications in indolosesquiterpene diversification
por: Zhang, Qingbo, et al.
Publicado: (2017)

xia2.multiplex: a multi-crystal data-analysis pipeline
por: Gildea, Richard J., et al.
Publicado: (2022)

Improved efficacy/safety profile of factor XIa inhibitor BMS‐724296 versus factor Xa inhibitor apixaban and thrombin inhibitor dabigatran in cynomolgus monkeys
por: Wong, Pancras C., et al.
Publicado: (2021)

Prevalence of the Metabolic Syndrome among rural original adults in NingXia, China
por: Yi, Zhao, et al.
Publicado: (2010)

Two Chinese Xia‐Gibbs syndrome patients with partial growth hormone deficiency
por: Cheng, Xinran, et al.
Publicado: (2019)

The complete mitochondrial genome of Traulia minuta Huang & Xia, 1985 (Orthoptera: Catantopinae)
por: Qiu, Zhongying, et al.
Publicado: (2021)

Thrombogenic potential of picomolar coagulation factor XIa is mediated by thrombin wave propagation
por: Parunov, Leonid A., et al.
Publicado: (2023)

EP-7041, a Factor XIa Inhibitor as a Potential Antithrombotic Strategy in Extracorporeal Membrane Oxygenation: A Brief Report
por: Pollack, Charles V., et al.
Publicado: (2020)

Xia–Gibbs syndrome in adulthood: a case report with insight into the natural history of the condition
por: Murdock, David R., et al.
Publicado: (2019)

Fluorescent Activity-Based Probe To Image and Inhibit Factor XIa Activity in Human Plasma
por: Modrzycka, Sylwia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ngbfrqemlgsfp4kfc53d80daq0